Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BAT6021 Alone or in Combination With BAT1308 in Advanced Solid Tumors
NCT05073484Phase 1Terminated
- Sponsor
- Bio-Thera Solutions, Ltd.
- Start
- Oct 2021
- Primary completion
- Mar 2023
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, open-label trial of BAT6021 in solid tumor (9 arms), sponsored by Bio-Thera Solutions, Ltd. Primary endpoints: Dose-limiting toxicity at 21 days and Serious adverse event at 90 days. Started Oct 2021; status: terminated.
02
Drugs
BAT6021
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT05073484.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05073484.